Fulcrum Therapeutics Stock Price, News & Analysis

Fulcrum Therapeutics, a biopharmaceutical firm focused on genetically defined rare diseases, has appointed Dr. Judith A. Dunn as President of Research and Development. Dr. Dunn brings over 25 years of experience in global drug development, previously serving as Vice President at Roche. Her expertise will support Fulcrum's losmapimod and FTX-6058 programs. The company aims to advance these programs, including two INDs in the next 24 months, leveraging its proprietary FulcrumSeek platform for drug target identification.

Fulcrum Therapeutics (Nasdaq: FULC) announced new data on imaging biomarkers and clinical assessments for facioscapulohumeral muscular dystrophy (FSHD) at the 2021 MDA Conference. Whole body musculoskeletal MRI (WB-MSK-MRI) provides vital information on disease severity. FSHD-TUG, a mobility assessment, shows correlation with clinical outcomes. The company is on track to report data from its Phase 2b ReDUX4 trial for losmapimod in late 2Q 2021. This clinical development aims to improve treatment options for FSHD, a condition affecting approximately 16,000 to 38,000 patients in the U.S.

Fulcrum Therapeutics reported a net loss of $17.7 million in Q4 2020, compared to $16.1 million in Q4 2019, and a total annual net loss of $70.8 million, down from $82.7 million in 2019. The company raised $50.6 million in gross proceeds from a public offering in January 2021, extending its cash runway into Q4 2022. Significant milestones are anticipated in 2021, including data releases from the Phase 2b trial of losmapimod in FSHD and Phase 1 trial of FTX-6058 for sickle cell disease. Fulcrum is discontinuing its Phase 3 COVID-19 trial to focus on rare diseases.

Fulcrum Therapeutics (Nasdaq: FULC) announces leadership changes effective March 31, 2021. Bryan E. Stuart, the current COO, will succeed Robert J. Gould, Ph.D., who is retiring but will remain on the Board as an advisor. Mark Levin will become executive chair. Stuart brings over 20 years of experience in rare diseases, and his leadership is expected to drive growth in Fulcrum’s clinical programs. Currently, Fulcrum is advancing therapies for facioscapulohumeral muscular dystrophy (FSHD) and sickle cell disease.

Fulcrum Therapeutics (Nasdaq: FULC) will announce its Q4 and full year 2020 financial results on March 4, 2021, prior to U.S. market opening. A conference call and webcast will follow at 8:00 a.m. ET to discuss the results and company updates. Fulcrum is advancing its proprietary product engine aimed at treating genetically defined rare diseases, with notable developments including losmapimod in Phase 2 for FSHD and Phase 3 for COVID-19, alongside FTX-6058 in Phase 1 for sickle cell disease.

Fulcrum Therapeutics (Nasdaq: FULC) recognizes Rare Disease Day 2021, emphasizing the importance of community support for those affected by rare diseases, especially during COVID-19. The company highlights challenges faced by patients with facioscapulohumeral muscular dystrophy (FSHD) and sickle cell disease (SCD) while announcing initiatives to raise awareness and foster connections within the rare disease community. Fulcrum's ongoing clinical developments include losmapimod for FSHD and FTX-6058 for SCD. The press release also underscores the absence of approved therapies for these conditions.

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company focused on genetically defined rare diseases, announced its upcoming participation in two virtual investor conferences. The SVB Leerink 10th Annual Global Healthcare Conference is scheduled for February 25, 2021, at 10:40 a.m. ET. The H.C. Wainwright Global Life Sciences Conference will feature a prerecorded fireside chat on March 9, 2021, at 7:00 a.m. ET. Audio webcasts will be accessible through the Investor Relations section of the Fulcrum website for 90 days after each event.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC) has successfully closed its public offering of 4,600,000 shares at $11.00 each, generating total gross proceeds of $50.6 million. This offering included 600,000 shares from underwriters exercising their option to purchase additional shares. The company aims to utilize these funds to advance its clinical trials for treatments targeting genetically defined rare diseases, including facioscapulohumeral muscular dystrophy and sickle cell disease.

Fulcrum Therapeutics has announced a public offering of 4,000,000 shares of its common stock at $11.00 each, totaling gross proceeds of $44 million, before expenses. The offering is fully underwritten and expected to close on January 22, 2021. Additionally, the underwriters have a 30-day option to purchase up to 600,000 more shares. The offering is registered under an effective shelf registration statement with the SEC. Funds from this offering will support the company's clinical programs for rare diseases.